By Danilo Masoni and Tom Westbrook MILAN/SINGAPORE (Reuters) – World stocks eased on Wednesday and bonds remained supported after a chorus of Wall Street bankers warned about a likely recession ahead, tempering optimism about China’s major shift in its tough zero-COVID policy. Top executives at Goldman Sachs, J.P. Morgan and Bank of America all sounded…
LONDON/PARIS (Reuters) – Shares of GSK and Sanofi surged in early trading on Wednesday, following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer. The ruling on Tuesday by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocked out about 50,000 claims in federal court, although it…
Wall Street futures edged lower Wednesday ahead of new employment and wholesale price data with the Federal Reserve gauging its next step in its fight to cool inflation. Futures for the Dow Jones Industrials slipped 0.4% and the S&P 500 fell 0.7% just over an hour before the opening bell. Stronger-than-expected economic data this week…
By Trixie Sher Li Yap SINGAPORE (Reuters) – Oil futures were little changed in Asia on Wednesday as hopes of improved Chinese demand offset uncertainty about how a Western cap on Russian oil prices would play out, keeping markets on edge after a sharp fall in the previous session. Brent crude futures edged up 3…
By Lewis Jackson SYDNEY (Reuters) – Major regional airlines say they expect to continue scheduled flights with New Zealand, which is beginning to ration jet fuel after a recent shipment failed government tests. Airlines are being told that jet fuel supplies at the country’s largest airport in Auckland will be throttled to 75% of planned…
BEIJING (AP) — China rolled back rules on isolating people with COVID-19 and dropped virus test requirements for some public places Wednesday in a dramatic change to a strategy that confined millions of people to their homes and sparked protests and demands for President Xi Jinping to resign. The move adds to earlier easing that…
WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders. With less than a month remaining in the year, the FDA’s drug center has granted 10 accelerated approvals — fewer than the…
